Saqib Islam was appointed chief executive officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as chief financial officer and chief business officer. Prior to joining SpringWorks Therapeutics, Saqib was chief business officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Prior to joining Moderna, Saqib served as executive vice president, chief strategy and portfolio officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities.
Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.
Francis Perier, Jr.
Chief Financial Officer
Frank Perier is Chief Financial Officer of SpringWorks. He was previously Chief Financial Officer at Forest Laboratories, Inc. for ten years prior to the company’s acquisition by Actavis. Prior to joining Forest, Mr. Perier was with Bristol-Myers Squibb Company for approximately nine years, where he worked in corporate and operations finance capacities of increasing responsibilities, including Vice President of Finance and Operations Planning – Americas Medicines Group, the company’s largest business unit at that time. Before joining Bristol-Myers Squibb, he was an accounting and auditing partner at Deloitte, where he worked for about 15 years. Mr. Perier was a member of the Board of Directors of Concordia International, Inc., a specialty pharmaceutical company, until September 2018 where he served on the Audit and the Human Resources and Compensation Committees of the Company.
Mr. Perier received a Master of Business Administration from the Stern School of Business, New York University and a Bachelor of Science in Accountancy from Villanova University. He is a Certified Public Accountant (inactive) and a member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.
Stephen Squinto, Ph.D.
Acting Head of Research and Development
Stephen Squinto, Ph.D., joined SpringWorks Therapeutics at launch in 2017 and is acting head of research and development. Steve is a venture partner with OrbiMed who brings over 25 years of biotechnology industry experience. Steve was a co-founder of Alexion Pharmaceuticals and recently served as its executive vice president and chief global operations officer. Prior to 2013, he was Alexion’s global head of research and development. From 1988 to 1992, Steve held various positions at Regeneron Pharmaceuticals. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Steve received his B.A. in chemistry and Ph.D. in biochemistry and biophysics from Loyola University of Chicago.
Jens Renstrup, M.D., MBA
Chief Medical Officer
Dr. Jens Renstrup is responsible for developing and driving execution of the clinical development programs and oversees medical affairs. Prior to joining SpringWorks Therapeutics, Jens was senior vice president and head of global medical affairs at Alexion Pharmaceuticals, where he helped to shape the company’s early- to late-stage development pipeline and was instrumental in building out a leading medical affairs function. Prior to Alexion, Jens served as vice president and head of global medical affairs at Glaxo Smith Kline Vaccines, where he developed the company’s medical strategy, which included evidence and engagement programs, and helped shape the development pipeline to support rapid drug applications in Europe, the United States and emerging markets. Jens also previously held progressive leadership positions at Merck & Co and started his career at IPSEN Scandinavia A/S.
Jens received a M.D. and specialist medical degree in anesthesiology and intensive care medicine from the University of Copenhagen, and an MBA from the Copenhagen Business School.
Badreddin Edris, Ph.D.
Chief Business Officer
Dr. Badreddin Edris is responsible for corporate strategy, business development and capital formation. His professional experience spans private and public equity investing, company formation and operations, corporate and business development, and strategic and product planning in the biotechnology industry. Prior to joining SpringWorks Therapeutics, Badreddin was an investment and operating professional on the private equity team at OrbiMed, where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. Badreddin also co-founded and held operating roles at two OrbiMed portfolio companies, Silverback Therapeutics (where he was chief business officer) and Edgewise Therapeutics (where he was chief operating officer). Before OrbiMed, Badreddin was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects.
Badreddin received his Ph.D. in genetics from Stanford University, where he was an NSF research fellow.
L. Mary Smith, Ph.D.
Senior Vice President, Clinical Research and Development
Dr. Mary Smith is responsible for designing and running the clinical development programs. Prior to joining SpringWorks Therapeutics Mary was the executive vice president of gene therapy at Bamboo Therapeutics, a wholly owned subsidiary of Pfizer where she led several key gene transfer programs for rare genetic diseases. Prior to joining Bamboo, Mary was vice president of product development at United Therapeutics, with responsibility for biological development in oncology, as well as regenerative medicine and virology.
Mary earned a Ph.D. in microbiology/immunology from the University of New Hampshire and received her post-doctoral training at Emory University.